Key Takeaways: One year on TRT is the full maturation point for most treatment effects. Body composition, mood, sexual function, and metabolic markers have reached or are approaching their plateau. The focus shifts from "getting better" to "staying better" -- maintaining gains, monitoring safety markers, and building on the hormonal foundation that TRT provides. Long-term data is reassuring: properly monitored TRT is safe for extended use.
The 1-Year Assessment: What the Data Shows
One year of testosterone replacement therapy represents a complete treatment cycle. Every tissue in your body has had time to respond, adapt, and reach a new equilibrium. The clinical data at 12 months is the most comprehensive snapshot of what TRT actually delivers.
The landmark studies that inform our understanding of 1-year TRT outcomes include:
Saad et al. (2011, 2016) -- registry studies following hypogonadal men on testosterone undecanoate for up to 12 years
The Testosterone Trials (TTrials, 2016) -- seven coordinated, placebo-controlled trials in men 65+ with low testosterone
Bhasin et al. (multiple) -- dose-response studies establishing the relationship between testosterone levels and outcomes
Isidori et al. (2005) -- meta-analysis of testosterone therapy outcomes
Here is what the aggregate evidence shows at 12 months.
Body Composition: The Full-Year Picture
Lean Mass
At 12 months, the Saad registry data shows:
Average lean mass increase: 4-6 kg (8.8-13.2 lbs) from baseline
The rate of gain slows significantly after month 6 but continues through month 12
Men who trained consistently gained more than sedentary men (no surprise, but the magnitude of the difference is large)
Gains plateaued for most men between months 9-12
In practical terms: A man who started TRT with low testosterone, trained 3-4 times per week, ate adequate protein, and was on a well-optimized protocol for 12 months has likely gained 8-12 lbs of lean mass. A man who was sedentary and changed nothing about his lifestyle gained 4-6 lbs.
Neither number is transformative by bodybuilding standards, but both are significant for health outcomes. Increased lean mass improves basal metabolic rate, glucose disposal, functional capacity, and long-term mortality risk.
Fat Loss
The fat loss data at 12 months is some of the most impressive in the TRT literature:
Average fat mass reduction: 4-6 kg (8.8-13.2 lbs) from baseline
Visceral fat reduction: 15-25% from baseline
Waist circumference reduction: 4-8 cm (1.5-3 inches) on average
Body fat percentage: typically 3-6% lower than baseline
Saad et al. documented progressive, sustained fat loss that continued through the full observation period (up to 12 years in some subjects), though the most rapid loss occurred in the first 6-12 months.
The fat loss is mechanistically driven by:
Testosterone's direct lipolytic effect on adipocytes
Improved insulin sensitivity reducing fat storage
Increased lean mass raising basal metabolic rate
Reduced cortisol sensitivity
Increased physical activity capacity and motivation
Net Body Recomposition at 12 Months
Metric
Average Change (12 Months)
With Consistent Training
Lean mass
+4 to +6 kg
+5 to +8 kg
Fat mass
-4 to -6 kg
-5 to -8 kg
Waist circumference
-4 to -8 cm
-5 to -10 cm
Body fat percentage
-3% to -6%
-4% to -8%
BMI
Often unchanged
Misleading metric on TRT
The scale may show minimal change because lean mass gain offsets fat loss. This is exactly why the scale is a poor measure of TRT progress and why DEXA scans, waist measurements, and progress photos are superior.
Cardiovascular Health at 1 Year
Cardiovascular safety has been the most debated aspect of TRT over the past decade. The 1-year data provides reassurance when therapy is properly managed.
Positive Cardiovascular Effects
Improved insulin sensitivity and reduced fasting glucose
Improved endothelial function (blood vessel dilation capacity)
Reduced visceral fat (a major cardiovascular risk factor)
Improved exercise capacity (both from hematocrit increase and from improved muscle mass and metabolism)
Areas Requiring Monitoring
Hematocrit: By 12 months, erythropoiesis has reached its plateau. Most men stabilize at a hematocrit 3-6% above baseline. Regular monitoring ensures it stays below the 54% threshold.
Lipids: HDL may decrease modestly (5-10%) during the first year. LDL effects are variable. Triglycerides typically improve. The net cardiovascular lipid impact appears neutral to slightly favorable in most studies.
Blood pressure: Most men see modest improvement or no change. A small subset experiences slight increases, particularly if hematocrit is elevated.
What the Large Studies Show
The TRAVERSE trial (2023), the largest randomized controlled trial of testosterone therapy to date (5,246 men, median follow-up 33 months), found that testosterone therapy did not increase the incidence of major adverse cardiovascular events compared to placebo. This was a pivotal finding that largely resolved the cardiovascular safety debate for properly managed TRT at replacement doses.
Bone Density
Bone mineral density is one of the few domains where improvement continues well beyond 12 months.
Testosterone affects bone through two pathways:
Direct androgen receptor activation in osteoblasts (bone-forming cells)
Estradiol conversion -- estrogen is actually the more important hormone for bone density in men, and adequate E2 from testosterone conversion is critical
At 12 months, DEXA scans typically show:
Lumbar spine BMD increase: 3-5%
Femoral neck BMD increase: 2-4%
These improvements continue for up to 36 months
For men with osteopenia or osteoporosis secondary to hypogonadism, this is one of the most clinically significant benefits of TRT. Fracture risk reduction takes longer to manifest but follows the BMD improvements.
Sexual function improvements reach their maximum between months 6-12 and then plateau. At one year:
Libido is at its treatment maximum -- stable, consistent, and reliable
Erectile function has reached its best hormonal response
Sexual satisfaction scores are at peak treatment effect
The novelty has normalized -- your improved sexual function is now your baseline
If sexual function is suboptimal at 12 months despite optimized testosterone and estradiol levels, the cause is essentially guaranteed to be non-hormonal. This is when thorough evaluation of vascular health, medication effects, pelvic floor function, and psychogenic factors becomes critical.
Cognitive and Psychological Function
Mood
At 12 months, the psychological effects of TRT are fully established and stable:
Depression scores in hypogonadal men improve significantly and remain improved
Anxiety symptoms are reduced
Emotional resilience to stress is consistently better
Motivation and goal-directed behavior are enhanced
The general quality of life measures are higher than pre-treatment
The TTrials found that the mood benefits were most pronounced in men who had significant depressive symptoms at baseline. Men with normal mood at baseline showed modest improvements that, while statistically significant, were smaller in magnitude.
Cognition
Cognitive effects at 12 months:
Working memory improvements are sustained
Verbal fluency remains enhanced
The "brain fog" resolution achieved in the first 3-6 months persists
Spatial reasoning and processing speed are at treatment maximum
Long-term cognitive data (beyond 1 year) is limited but suggests that the benefits persist as long as testosterone levels remain in the therapeutic range.
Long-Term Safety: What the Evidence Says
One year is a good point to address the long-term safety question honestly.
Prostate
PSA should be monitored annually. A stable PSA is reassuring.
Testosterone therapy does not cause prostate cancer. This was a long-held belief based on a misinterpretation of Huggins' 1941 work. Modern evidence, including the TTrials and TRAVERSE, shows no increased prostate cancer incidence with testosterone therapy.
However, testosterone can accelerate the growth of existing prostate cancer. Men should have appropriate screening (PSA + digital rectal exam) before starting and annually thereafter.
Cardiovascular
TRAVERSE trial: no increased cardiovascular events with testosterone therapy
Saad registry data (up to 12 years): cardiovascular event rate was actually lower in testosterone-treated men than in matched controls
Hematocrit management is the key modifiable cardiovascular risk factor on TRT
Fertility
By 12 months, most men on TRT without HCG co-therapy have significantly suppressed or absent sperm production
Recovery of spermatogenesis after TRT discontinuation typically takes 6-18 months
Men who want future fertility should use HCG concurrently or have a clear plan for temporary discontinuation
Liver and Kidney
Injectable and transdermal testosterone do not have clinically significant hepatotoxicity (unlike oral methylated androgens)
Kidney function is not adversely affected by testosterone therapy
Standard metabolic panels at annual checkups are adequate monitoring -- a good clinic handles this routinely as part of your protocol (see our clinic reviews)
Psychological Dependence
This is rarely discussed but worth addressing honestly. After a year on TRT, you know what "normal" feels like. The prospect of returning to pre-treatment symptoms is profoundly unappealing. This is not addiction -- it is rational preference for feeling healthy. However, it does mean TRT is effectively a lifelong commitment for most men.
Diminishing Returns: Understanding the Plateau
The concept of diminishing returns on TRT is important to frame correctly.
What plateaus:
The hormonal restoration effects (mood, energy, libido, sexual function) reach their ceiling between 6-12 months
Muscle gain from testosterone itself approaches a saturation point as androgen receptors in muscle are fully occupied
Fat loss from hormonal effects alone slows significantly
What does not plateau:
The training and lifestyle benefits that TRT enables continue compounding. A man who has been training for 12 months with optimized testosterone has a dramatically different capacity than a man with 3 months.
Bone density continues improving
Metabolic health continues improving (especially if body composition improvements are maintained)
Cardiovascular benefits accrue over years
The shift at year 1 is from hormonal restoration to optimization and lifestyle leverage. TRT gave you the foundation. What you build on it from here is driven by training, nutrition, sleep, and overall health management.
The Annual Review: What to Discuss with Your Provider
Is your current injection frequency working, or would adjustments improve stability?
Any side effects that need management?
Fertility considerations -- any changes to family planning?
Are you hitting your fitness goals with the current protocol?
The Honest Conversation
Year 1 is also the time for an honest assessment: Is TRT delivering what you expected? If the answer is no, it is worth examining whether the issue is:
After the first year, TRT management becomes more routine:
Bloodwork every 6-12 months (more frequently if managing hematocrit or other issues)
Annual PSA screening
Annual cardiovascular risk assessment
Protocol adjustments as needed (aging, weight changes, and other health factors may alter your optimal dose)
Continued focus on training, nutrition, and lifestyle as the primary drivers of progress
The men who do best long-term on TRT are those who view it as one component of a comprehensive health strategy. Testosterone replacement fixes one variable -- hormonal adequacy. Everything else that makes a man healthy, fit, and functional still requires effort.
One year in, you have the foundation. Build on it.
This content is for informational purposes only and is not medical advice. Consult a qualified healthcare provider before starting any treatment.
Frequently Asked Questions
Do TRT benefits continue after the first year?
Most acute benefits (energy, mood, libido, body composition) plateau between 9-12 months. However, bone density continues improving for up to 3 years, and body recomposition can continue indefinitely with consistent training.
Is TRT safe to take for life?
Current evidence supports long-term safety when properly monitored. The Saad et al. registry studies followed men for up to 12 years with ongoing benefits and no increase in cardiovascular events. Regular monitoring of hematocrit, PSA, lipids, and cardiovascular health is essential.
Will I have diminishing returns on TRT?
Hormonal benefits plateau, yes. But the foundation TRT provides -- stable testosterone, healthy metabolism, adequate recovery -- continues supporting your health and fitness goals. The 'returns' shift from hormonal restoration to what you build on that foundation.
What bloodwork should I get at 1 year on TRT?
A comprehensive panel including total and free testosterone, estradiol (sensitive), CBC with hematocrit, CMP, lipid panel, PSA, fasting glucose/HbA1c, and thyroid panel. A DEXA scan for body composition and bone density baseline is also valuable.
Can I stop TRT after a year if my levels are good?
TRT does not restore natural production. If you stop, testosterone levels will return to (or below) pre-treatment levels, and symptoms will return. TRT for primary or age-related hypogonadism is typically a lifelong commitment.
